Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation

Blood

Volumn 121, Issue 18, 2013, Pages 3745-3758

  Blyth, Emily ^a,b,c   Clancy, Leighton ^a,b   Simms, Renee ^a   Ma, Chun K K ^a   Burgess, Jane ^a   Deo, Shivashni ^a   Byth, Karen ^b,c   Dubosq, Ming Celine ^b   Shaw, Peter J ^c,d   Micklethwaite, Kenneth P ^a,b,c   Gottlieb, David J ^a,b,c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

FOSCARNET; GANCICLOVIR; METHYLPREDNISOLONE; THYMOCYTE ANTIBODY; VIRUS ANTIGEN; ANTIVIRUS AGENT;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADOPTIVE TRANSFER; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIVIRAL THERAPY; ARTICLE; BACTERIAL INFECTION; BONE MARROW SUPPRESSION; BRAIN HEMORRHAGE; CANCER SURVIVAL; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; COHORT ANALYSIS; COLITIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; CYTOMEGALOVIRUS RETINITIS; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; FEMALE; FOLLOW UP; GRAFT FAILURE; HUMAN; INFECTION PREVENTION; LONG TERM CARE; LUNG ADENOCARCINOMA; MALE; MICROANGIOPATHY; MYCOSIS; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PULMONARY HYPERTENSION; SECOND CANCER; VIRUS PNEUMONIA; VIRUS REACTIVATION; VIRUS REPLICATION; ADOPTIVE IMMUNOTHERAPY; ALLOTRANSPLANTATION; BLOOD; CASE CONTROL STUDY; DONOR; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; MIDDLE AGED; MORTALITY; PHASE 2 CLINICAL TRIAL (TOPIC); PRESCHOOL CHILD; STATISTICS; T LYMPHOCYTE; TRANSPLANTATION; VIRUS ACTIVATION;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS, PHASE II AS TOPIC; COHORT STUDIES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; FOLLOW-UP STUDIES; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MALE; MIDDLE AGED; T-LYMPHOCYTES; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS; VIRUS ACTIVATION; YOUNG ADULT;

MLCS; MLOWN;

EID: 84879729427     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-08-448977     Document Type: Article

References (35)

1. Gandhi MK, Khanna R. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis. 2004;4(12):725-738. (Pubitemid 39574344)
2. Boeckh MJ, Leisenring W, Riddell SR, et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood. 2003;101(2):407-414. (Pubitemid 36077556)
3. Ozdemir E, Saliba RM, Champlin RE, et al. Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies. Bone Marrow Transplant. 2007;40(2):125-136. (Pubitemid 47046210)
4. Nguyen Q, Champlin R, Giralt S, et al. Late cytomegalovirus pneumonia in adult allogeneic blood and marrow transplant recipients. Clin Infect Dis. 1999;28(3):618-623. (Pubitemid 29242543)
5. Boeckh MJ, Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood. 2009;113(23):5711-5719.
6. Green ML, LeisenringW, Stachel D, et al. Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of Cytomegalovirus disease after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012;18(11):1687-1699.
7. Wills MR, Okecha G, Weekes MP, Gandhi MK, Sissons PJG, Carmichael AJ. Identification of naive or antigen-experienced human CD8(1) T cells by expression of costimulation and chemokine receptors: analysis of the human cytomegalovirus-specific CD8(1) T cell response. J Immunol. 2002;168(11):5455- 5464. (Pubitemid 34556123)
8. Beninga J, Kalbacher H, Mach M. Analysis of T helper cell response to glycoprotein H (gpUL75) of human cytomegalovirus: evidence for strainspecific T cell determinants. J Infect Dis. 1996;173(5):1051-1061. (Pubitemid 26251445)
9. Beninga J, Kropff B, Mach M. Comparative analysis of fourteen individual human cytomegalovirus proteins for helper T cell response. J Gen Virol. 1995;76(Pt 1):153-160.
10. Sylwester AW, Mitchell BL, Edgar JB, et al. Broadly targeted human cytomegalovirus-specific CD41 and CD81 T cells dominate the memory compartments of exposed subjects. J Exp Med. 2005;202(5):673-685. (Pubitemid 41248418)
11. Einsele H, Roosnek E, Rufer N, et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood. 2002;99(11):3916-3922. (Pubitemid 35332029)
12. Feuchtinger T, Opherk K, Bethge WA, et al. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood. 2010;116(20):4360-4367.
13. Schmitt A, Tonn T, Busch DH, et al. Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specific CD81 T. Transfusion. 2010.
14. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science. 1992;257(5067):238-241.
15. Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED, Riddell SR. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor N Engl J Med. 1995;333(16):1038-1044.
16. Peggs KS, Verfuerth S, Pizzey A, Khan N, Guiver M, Moss PA, Mackinnon S. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virusspecific T-cell lines. Lancet. 2003;362(9393):1375-1377. (Pubitemid 37338339)
17. Perruccio K, Tosti A, Burchielli E, et al. Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood. 2005;106(13):4397-4406. (Pubitemid 41775954)
18. Cobbold M, Khan N, Pourgheysari B, et al. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med. 2005;202(3):379-386. (Pubitemid 41126955)
19. Mackinnon S, Thomson K, Verfuerth S, Peggs KS, Lowdell M. Adoptive cellular therapy for cytomegalovirus infection following allogeneic stem cell transplantation using virus-specific T cells. Blood Cells Mol Dis. 2008;40(1):63-67. (Pubitemid 350192302)
20. Peggs KS, Thomson K, Samuel E, et al. Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation. Clin Infect Dis. 2011;52(1):49-57.
21. Micklethwaite KP, Hansen A, Foster AE, et al. Ex vivo expansion and prophylactic infusion of CMVpp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2007;13(6):707-714. (Pubitemid 46767999)
22. Micklethwaite KP, Clancy L, Sandher U, et al. Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene-modified dendritic cells after allogeneic hemopoietic stem cell transplantation. Blood. 2008;112(10):3974-3981.
23. Moosmann A, Bigalke I, Tischer J, et al. Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells. Blood. 2010;115(14):2960-2970.
24. Leen AM, Myers GD, Sili U, et al. Monoculturederived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med. 2006;12(10):1160-1166. (Pubitemid 44527351)
25. van Rhee F, Savage D, Blackwell J, et al. Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: equal efficacy of lymphocytes from sibling and matched unrelated donors. Bone Marrow Transplant. 1998;21(10):1055-1061. (Pubitemid 28230672)
26. Peggs KS, Thomson K, Hart DP, et al. Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. Blood. 2003;103(4):1548-1556. (Pubitemid 38168677)
27. Marks DI, Lush R, Cavenagh J, et al. The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood. 2002;100(9):3108-3114. (Pubitemid 35217056)
28. Heslop HE, Slobod KS, Pule MA, et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2009;115(5):925-935.
29. Doubrovina E, Oflaz-Sozmen B, Prockop SE, et al. Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV1 lymphomas after allogeneic hematopoietic cell transplants. Blood. 2012;119(11):2644-2656.
30. Melenhorst JJ, Leen AM, Bollard CM, et al. Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects. Blood. 2010;116(22):4700-4702.
31. The Australian Clinical Trials Register. 2012; http://www.anzctr.org.au.
32. Leen AM, Christin A, Myers GD, et al. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. Blood. 2009;114(19):4283-4292.
33. Feuchtinger T, Matthes-Martin S, Richard C, et al. Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. Br J Haematol. 2006;134(1):64-76. (Pubitemid 43830030)
34. Ramadan G, Konings S, Kurup VP, Keever-Taylor CA. Generation of Aspergillus- and CMV- specific T-cell responses using autologous fast DC. Cytotherapy. 2004;6(3):223-234. (Pubitemid 38868095)
35. Gerdemann U, Vera JF, Rooney CM, Leen AM. Generation of multivirus-specific T cells to prevent/treat viral infections after allogeneic hematopoietic stem cell transplant. J Vis Exp. 2011;(51):2736.